BVNKF:OTCMKTS
Bavarian Nordic A/S
36,06 USD
0,00%
(0,00) 1D
8-окт., 15:46:25 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNKF...
Mkt. cap
2,80 млд
Avg. vol.
14,00
Volume
0,00
52-wk high
37,22 USD
52-wk low
27,69 USD
Beta
1,46
Shares outstanding
79,26 млн
No. of employees
2 миң
Mkt. cap
2,80 млд
Avg. vol.
14,00
Volume
0,00
52-wk high
37,22 USD
52-wk low
27,69 USD
Beta
1,46
Shares outstanding
79,26 млн
No. of employees
2 миң
News stories
From web sources and news partners
Simply Wall Street
·
26 мүнөт мурун
Palo Alto Networks (PANW) Becomes Founding Partner In Critical Infrastructure Defense Program
Investing News Network
·
43 мүнөт мурун
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
Reuters
·
36 мүнөт мурун
Wall St slides as hot CPI data fuels rate-hike bets; chips, banks weigh
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1,91 миң
Founded1992-ж., 1-июл.
Headquarters-
Sector-
Websitebavarian-nordic.com